AbCellera Biologics Inc.
2125 East Mall, Suite 305
48 articles with AbCellera Biologics Inc.
9/6/2019Biopharma companies strengthen the C-suite and board of directors with these appointments.
AbCellera announced the expansion of its executive team with the hiring of Andrew Booth as Chief Financial Officer and Tryn Stimart as General Counsel.
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases.
AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.
AbCellera Announces Partnership with NIAID Vaccine Research Center and Ichor Medical Systems to Tackle Pandemic Viral Outbreaks
The AbCellera-led team will collaborate in an ambitious capability demonstration for the rapid generation of antibody-based countermeasures against a pandemic strain of influenza
AbCellera announced a two-year agreement with the Bill & Melinda Gates Foundation to help accelerate global health research.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
AbCellera and Denali Therapeutics Sign Expanded Multi-Year, Multi-Target Deal to Discover Therapeutic Antibodies for Neurological Diseases
AbCellera announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Multi-year agreement will provide access to AbCellera’s expertise and state-of-the-art antibody discovery technology for up to ten clinically-relevant disease targets.
Novartis announced that the FDA approved the company’s Egaten to treat fascioliasis in patients six years of age and older. Novartis also inked a multi-target and multi-year collaboration with AbCellera.
AbCellera’s antibody discovery engine will isolate novel antibodies for the development of targeted CAR-T cell therapy
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases
AbCellera expands its antibody discovery capabilities by capturing foundational repertoire sequencing technology from immune profiling start-up.
AbCellera Announces Collaboration with Denali Therapeutics to Discover New Antibodies to Treat Neurodegenerative Diseases
Collaboration uses AbCellera’s high-throughput single-cell screening capabilities to find new antibodies against a target identified by Denali linked to neurodegenerative disorders
AbCellera and Harbour Antibodies Announce Technology Co-Offering Agreement for Next-Generation Fully-Human Antibody Discovery
Co-offering combines AbCellera’s microfluidic single-cell screening platform with Harbour’s H2L2 transgenic mouse technology to create an end-to-end solution for the discovery of fully-human lead therapeutic antibodies.
AbCellera Awarded Multi-Year Contract to Lead the Development of a Rapid Response Platform Against Pandemic Viral Threats
AbCellera Biologics Inc. announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks.
LifeSciences BC is pleased to announce the recipients of the 20th Annual LifeSciences BC Awards.
AbCellera Announces 25th Partnered Program and New Antibody Discovery Partnership with Global Biotech
AbCellera Biologics Inc. announced today a new therapeutic antibody discovery collaboration with an undisclosed mid-cap public biopharmaceutical company.